University of Groningen Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine Martines, Anne-Claire
Hele tekst
(2) Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine From computational model to mice to man. Anne-Claire M.F. Martines.
(3) ǡ ǡ ǡ ǡ Ǥ Ǥ
(4) ȋ
(5) ȌǤ ǣ.
(6) ȋ
(7) ȌǤ ȋ Ȍ ȋ Ȍ ȋǤǤȌ ǤǤ ǣ ǣ Ǧ Ǥ ȋΪ Ǧ Ȍǡ ȋ Ȍ ȋ͵ͲͶǦ ȋ
(8) ǣ Ͷͳ͵Ȍȋ
(9) ǣʹ
(10) Ȍǡ ȋ
(11) ǣʹͻͺͷͲͺȌȌ ǣǦǤ Ǥ ǣ ȁǤǤ
(12) ǣ ͻͺǦͻͶǦͲ͵ͶǦͳͻͻǦͺȋȌ ͻͺǦͻͶǦͲ͵ͶǦͳͻͺǦͳȋȌ ̹ǤǤ ǤǡʹͲͳͻ Ǥ ǡ ǡǡ ǡ Ǥ.
(13) Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine From computational model to mice to man. Proefschrift. ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 10 juli 2019 om 16.15 uur. door. Anne-Claire Micheline Francisca Martines geboren op 10 oktober 1981 te Willemstad, Curaçao.
(14) Promotores Prof. dr. B.M. Bakker Prof. dr. D.J. Reijngoud. Beoordelingscommissie Prof. dr. F.J. Bruggeman Prof. dr. A.K. Groen Prof. dr. F.J. van Spronsen.
(15) This PhD thesis is dedicated to my lovely parents, Ingrid Martines-Kirindongo and Edwin Martines, and my loving husband, Amart Schoop, who have always supported me through thick and thin.
(16) Paranymfen Natasha Tearr-Marcos Aduni Mariana.
(17) CONTENTS Chapter 1. Chapter 2. Chapter 3. Chapter 4. Chapter 5. Chapter 6. Chapter 7. Appendix. . Ǧ ͵ǦǦ Ǧ Ǧ Ǧ ΪǦ Ǧ Ǧ ǣ Ǧ Ǧ Ǧ in vitro Ǥ . . 9. 39. 67. 127. 157. 205. 225. 241 243 249 255 265 269 273.
(18)
(19) Chapter 1 General introduction and outline of the thesis . . .
(20)
(21) General introduction and outline of the thesis. Introduction Ǥ Ǥ Ǥ Ǥ ǡ ȏͳȂͶȐǤǡ ȏͷȂͳ͵ȐǤ Ǥ ȏ͵ǡͳͶȂͳȐǤ. Common acquired metabolic diseases Ǧ ǡ ȏͳͺȐǤ Ǧ Ǥ ǡ ͳͻͷȏͳͻȐǤ ǡ ͳͻΨȋͳʹǤͷΨ͵ͺΨȌȏʹͲȐǡ ǡ ʹȋʹȌǡ ȋ ȌȏͳȂͶȐǤʹǡ ȏʹͳǡʹʹȐǤ ȋ Ȍ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ȏʹͳǡʹ͵ȂʹͷȐǤ ȋ Ȍ ʹͲΨǡ ȏʹȂʹͻȐǤ ȋȌ ȋi.e. Ȍ ȏ͵ͲȂ͵͵ȐǤ Ǧ ǡ ȏ͵ͶȂ͵ȐǤ ȾǦ ǡ ȋȌ Ǥ ǡ ʹ ȋʹȌǤ Ǧ ȏ͵ȐǤ ȾǦ ȏ͵ȐǤ ȏ͵ͺǡ͵ͻȐǤ ǡǦǦ ȏ͵ȐǤ ȏͶͲȐǤ ǡ ǡ ȏͶͲȐǡ ȏͶͲȐǤ ǡ Ǥ Ǥ
(22) ǡ ͳͳ. 1.
(23) Chapter 1 ǡ ȏͳͷǡͶͲǡͶͳȐǤ ǡ ȏͳͷȐǤ ǡ ȋ Ȍǡ ʹǡ ȏͶʹȐǤ
(24) ǡ ǡ ǡ Ϊǡ Ǥǡ
(25) ȋ ȌǤ . Metabolites and common acquired metabolic disease Lipid regulators Ǥ ǡ Ǧ Ǥǡ ǡ ǤͳǣͳǦȏͶ͵ǡͶͶȐǤ Ǥ ȏͶ͵ȂͶȐǤ
(26) Ǧ Ǥ Ǧ Ǧ ȋ ȌǤ de novo Ǥ ǡ Ǧ ǦǦ Ǧ ȋ Ȍǡ ǡ ǡ ǡ ȏͶȐǤ ǡ ǡ Ǧ͵ Ǧ ǡ Ǧ ȏͶͺȂͷͲȐǤ . NAD+ Ϊ ǡ ǡ ǡ ǡ ȏͷͳȂͷ͵ȐǤ
(27) ǡ Ϊǡ ȏͷʹȂͷͶȐǤ
(28) ǡ Ϊ ǤΪ ʹǡΪǦ ͳ ȋ
(29) ͳȌ Ǧ ȾǦ Ǥ
(30) ͳ ǤΪ ǦǦǦ ȏͶʹȐǤΪ
(31) ͳ Ǥ Ϊ ǡ
(32) ͳ Ϊ ǦǦǦ ȏͶʹȐǤΪ Ǧ ǤΪ ǡΪǦ ͵ͺǡ Ǥ ΪǦ Ǥ. ͳʹ.
(33) General introduction and outline of the thesis SIRT1Ϊ Ǧǡ ǡ ȏͶʹȐǤ . Coenzyme A ȏͷͷȂͲȐǤ Ǥ
(34) de novoǡ ǡ ǡ Ǥ
(35) ǡ ȋ ǡ ȋȂ ȌȌǤ
(36) ʹǤ ǡ PANK1 ǡ ǡǦ ȏͷͷȐǤ ob/obʹ ǡ ȋ Ȍǡ ȏͳǡʹȐǤPANK1 ǡ ȾǦ ǡ ǡ Ǥ ǡǡǡ ȏͷͷȐǤ Ǧ ǡ Ǧ ǦǤ ͳǤ
(37) ǡ ǡ ȋ ͷȌǡ Ǥ ǡǤͳ ǡ ȏ͵ȐǤ
(38) ʹǡͳ Ǧ in vitroǡ ȋȌǦ ȋȌȏͶȐǤ . Amino acids ǡ ȏͷȐǤ ǡ Ǥ ǡ Ǧ ȋȌǡǡ Ǥ ȋȌ ǡ ȋ ȌǤ
(39) ǡ Ǧ ȏͶͶǡȐǤ ǡ ȏͶͶȐǤ ʹȏͶͶȐǤ ͳ͵. 1.
(40) Chapter 1. Advances in approaches and methods to study acquired metabolic diseases Bioinformatic approaches Ǧ Ǧ ǡ Ǧ ȋ Ȍǡ ȏȐǤǦ ǡǦ Ǥ ǡǡ Ǥ ȏȐǤ DzǦ dz Ǥ ǡ Ǧ Dz dz Ǧ ǡ Ǧǡ ȋ Ȍ Ȁ ȏͺȐǤ . Experimental models Ǥin vitro Ǥ ǡǡ ʹ ȏͳͶǡͻǡͲȐǤ ǡ ǡ Ǥǡ ǡ Ǥ ǡ ȏͳͶǡͻȐǤ ǡ ȏͳȐǤ ǡin vitro ex vivo ǡ ǡ ȏͻǡʹȐǤ ǡ ǡ Ǧ ǡǦ ȋȌǦ ȏͻǡʹȂȐǤ . Analytical methods and data analysis
(41) ǡ Ǥ DzǦ dz ǡ Ǧ ȏͳͶǡʹͳǡͻǡȂͺͲȐǤ ǡ ȋȌ ǡ Ǧǡ ǡ ȏͷǡǡȂͺ͵ȐǤ ǡ Ǥ ǦǦ ȋ ȌȏͺͶȐǤ ǡ setsǤ ǡ Ǥ ǡ Ǥ . ͳͶ.
(42) General introduction and outline of the thesis ȋȌǡ Ǥ ǡ ǦǦ ȋ
(43) Ȍ Ǧ ǡ ǡ Ǥ ǦǤ Ǧ Ǧǡ Ǧ ȏͺͶȂͺȐǤ ǡ Ǥ . ȏͺͺȐǡ ȏͺͻȐǡ ȏͻͲȐ ȏͻͳȐǡ Ǧ ǡ Dz dz ȏͻʹȐ Dz dzȋ Ȍȏͻ͵ǡͻͶȐ Ǥ Dz dzǦ Ǧ Ǧ ͵ʹǡ εͻͲΨ Ǧ ȏͻʹȐǤ Ǧ Ǥ
(44) ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ȏͻͷȂͳͲͲȐǤ . Systems biology and computational modeling ǡ ǡ ȏͳͲͳȂͳͲͶȐǤ Ǧ ȏͻͷȂͳͲͲǡͳͲͷȂ ͳͳͲȐǤ Ǧ Ǥ Ǧ ǡ Ǧ ǡ ǡǡǡ ȏͳͳͳȐǤ ǡ Ǥ ǤiHepatocytes2322ǡǦ ǡ ȏͻͻȐǤ ʹ ȏͻȐ ȏͳͳʹȐǤ ǡʹͲǡǡ ǡ ǡ ǡǦ Ǧȋ Ȍȏͳͳ͵ȐǤ Ǥ Ǥ ȏͳͳͳǡͳͳͶȐǤ Ǧ ǦǡǦ ȏͳͳͳȐǤ ͳͷ. 1.
(45) Chapter 1 ǡ Ǥ ǡǤ ȋȌ ǡ ǡ Ǥ Ǥ ȏͳͳͷȂͳͳͺȐǤ DzǦdz Ǥ
(46) ǡ Ǥ Ǥ ȏͳͳͻȐǤ ǡ ǡ Ǥ Ǧ ȏͳʹͲȐǤǡ Ǥ
(47) ǡ Ǥ ǡ in silicoǡin vitro or in vivo ȏͳͳͳȐǤ ȏͳʹͳȐǡ ȏͳͲǡͳʹʹȐǡ ǡ ȏͳʹ͵Ȑǡ Ǧ ȾǦ ȏͳʹͶȐǡ ȏͳʹͷȐǡ Ǧ ȏͳͲͺȐǤ ǡ Ǧ Ǥ . Inborn errors of metabolism/Inherited metabolic diseases
(48) ȋ
(49) Ȍ Ǥ
(50) ͳȌ ǡ Ǧ ǡ ʹȌǡ Ǧ Ǧ ǡ͵Ȍ ǡ ȏͳʹȐǤ Ǥ ǡ
(51) ͳȀʹͶͲͲ ʹͲͲ͵ͳȀͳͺͻͶ
(52) ʹͲͳͷȏǡͻǡͳͲǡͳͺǡͳͲʹǡͳʹȐǤ
(53) Ǧ ǦȋȌ ȋȌȏͺȂͳͲǡͳͺǡͳͲʹǡͳʹȐǤ ͳȀͺ͵ͲͲ ʹͲͲʹͲͳͷ ȏͳʹͺȐͳȀͻͲͻ͵
(54) ʹͲͳͷȏȐǤ Ǧ Ǥ
(55) Ǥ ǡ ȏͳͲǡͳͲʹǡͳʹȐǤ ͳ.
(56) General introduction and outline of the thesis. 1. . Common principles underlying IEMs and acquired metabolic diseases
(57) ǡǦ Ǥǡ
(58) ǡǤ ǡ
(59) ǡ ǡ ȏͳͺǡͳͲʹǡͳʹͻȐǤ
(60) ǡ ȋ ȏͳ͵ͲȐȌǡ ǡ ȏͳͺȐǤ
(61) ǡ ǡ ǡ ǡ
(62) ȏͳͺǡͳ͵ͳǡͳ͵ʹȐǤ
(63) Ǥ
(64) ǡ Ǥ ȏͳͺȐǤ
(65) Ǥ Ǥǡ Ǥ Dz ̶ ȋ ̶̶Ȍ Ǥ Ǥ Ǧ ȋȌ ͺǦ ǡȏͳͺǡͳ͵͵ȐǤ ǡ
(66) ȋ Ȍ Ǧ Ǥ ǡ ȋ Ȍ
(67) Ǥ ǡ Ǧ
(68) ȋǦȌǤ
(69) ǡ
(70) Ǥǡ
(71) Ǥ ǡ
(72) Ǥǡ Ǥ
(73) ǡ Ǧ ǡ ǡ Ǧ Ǥ
(74) ʹͲ ȏǡͳͲǡͳͺǡͳ͵ͶȐǤ Ǥ ǡ ǡ ACADM ͳͲΨ ǡ ȏͳ͵ͶȐǤ ACADM ͺǦ ȏͳͺǡͳ͵͵ȐǤ
(75) Ǥ Ϊǡ ǡ Ǥ Ϊ ͳ.
(76) Chapter 1
(77) ȋ
(78) Ȍ ȏͳ͵ͷȂͳ͵ȐǤ
(79) ǡ ǡ ȏͳ͵ͷȂͳͶʹȐǤ
(80) ͵Ǧ Ǧ ǦǦǦ Ǧȋǡ Ȍ ͵Ǧ Ǧ͵Ǧʹȋ ʹȌ ȏͳ͵ͻǡͳͶͲȐǤ ʹ Ǥ
(81) ͵ ȏͳͶͲȐǤǡǡ Ǥ
(82) Ϊ
(83) ȏͳ͵ǡͳͶ͵ǡͳͶͶȐǤ
(84) Ǥǡ
(85)
(86) ǡȋ Ȍ ȋȌȏͷͻǡͲȐǤ . Computational modeling and omics in IEMs ǡ
(87) Ǥ
(88) ǡ ͳǦȏͳͶͷȐǦ ʹΨ͵
(89) ȏͳͶȐǡ ͵ͺ
(90) ȏͻͻȐǤ ʹǤʹǡ ͶΨ Ͷͷ Ǧ
(91) ȏͳͳʹȐǤ
(92) Ǥǡǡ Ǧ Ǧ ȏͳͲͶǡͳͲǡͳͶȐǤ
(93) ǡ Ǥ
(94) Ǧ ȏͳͶͺȐǤ . Mitochondrial fatty-ĂĐŝĚɴ-oxidation (mFAO) and mFAO deficiency Ǧ Ǥ Ǥ Ǧ ǡ Ǧ ȾǦ ȋ Ǧ Ȍ ǦǤ DzȾdz DzȾǦ dz Ƚȋ ȌȾ ȋ Ȍ Ǧ ǡ Ǧ Ǧ Ǥ ǡ Ǥ
(95) ǡ Ǥ Ǥ ȋ ͳȌǤ. ͳͺ.
(96) General introduction and outline of the thesis. 1. Malonyl-CoA. Palmitoyl-CoA. Acyl-carnitine. carnitine. CoASH carnitine. CPT1 CACT. C16. CPT2. C4-C16. Mitochondrion. C4-C16. carnitine. CoASH carnitine. Acyl-carnitine Acyl-CoA. MCKAT C4-C16. Acetyl-CoA CoASH. SCAD. MCAD. LCAD. VLCAD. C4-C6. C4-C12. C8-C16. C12-C16. Enoyl-CoA. Ketoacyl-CoA. MSCHAD C4-C16. NADH + H+ NAD+. H2 O C4-ketoacyl-CoA. CROT C4-C16. Hydroxyacyl-CoA. FAD FADH2. Acetyl-CoA NADH + H+ C4-ketoacyl-CoA NAD+ CoASH. MTP C8-C16. . Figure 1. Schematic representation of the rodent mFAO pathway. ǣ Ǣǣ Ǧ ȋi.e.ǦȀ Ǧ ȌǢ ǣ Ǧ Ǧ ȋi.e. ȌǤ Ǥ. ȋȌ ͳͳͺ Ǥ Ǥ Ǧ ȋ Ȍ ǦȏͳͶͻǡͳͷͲȐǤ Ǧ ǦǤ Ǧ Ǥ Ǧ Ǥ
(97) ȋͳȌǡ Ǧ Ǧ ȋȌǡ
(98)
(99) ȋʹȌǤ ǡ Ǧ Ǧ ǡ Ǧ Ǥ Ǧ Ǧ Ǥ ǡ Ǧ Ǧ ʹǤ Ǧ Ǧ Ǧ Ǥ Ǧ Ǧȋ Ȍ Ǧ ȋ ͳȌǤ
(100) ǡ Ǧ Ǧ ȏͳͷͳȂͳͷ͵ȐǤ Ǥ Ǧ ȏͳͲͺǡͳͷ͵ȐǤ Ǥ ǡ Ǥ Ǥ Ǧ ǣǦǦǡǦǡǦǡǦ Ǧ ǡ ǡ ǡ Ȍ ȋȌ ȋǤǤ ͳǤ͵ǤͻͻǤ͵ ǤǤͳǤ͵ǤͺǤͳȌǤ Ǧ ǡ Ǥ Ǧǡ ȏͺͲȐ ȏͳͷ͵ȐǤ
(101) ǡ Ǧ ͳʹǦͳǡͺǦͳǡͶǦͳʹͶǦ . ͳͻ.
(102) Chapter 1 ǡ ǡ ǡ ǡ Ǧ Ǧͳǡ ͶǦͳ ͶǦ ǡ ǡ Ǥ Ǧ ǡ Ǥ ǡ Ǥ Ǧ Ǧȋ ͳȌǤǦͺ ͵ ȋȌǤ
(103) ǦǦ Ǥ ǡ Ǧ Ǧ ͵ ǣǦ ȋǡǤǤͶǤʹǤͳǤͶǤǤͶǤʹǤͳǤͳͷͲȌǡ Ǧ ȋȀ ǡ ǤǤͳǤͳǤͳǤʹͳͳ ǤǤ ͳǤͳǤͳǤ͵ͷȌ Ǧ ͵ǦǦ Ǧ ȋǡ ǤǤ ʹǤ͵ǤͳǤͳȌȌǡ Ǥ Ǧ Ǥ
(104) Ǧ ǦȀ Ǧ Ǥ Ȁ Ϊ ǡ Ǥ Ȁ Ǧ Ǧ Ϊ Ǥ ȏͳͲͺȐ Ǥ
(105) ȋʹǤͳȉͳͲǦͶȌ Ǥ
(106) ǡ ǡ Ǧ Ǧ ǦǤ ͳͲ͵ȏͳͷ͵ȐǤ Ǧ Ǥ ǡ ǡ Ȁ ǣ ǡ ǦȋǤǤʹǦǦʹǦǦȌʹǦǦ͵Ǧ Ǧǡ ʹǦ Ǧ Ǧ ǦȏͳͷͶȂͳͷȐǤ Ǥ Ǥ ͳǡǡʹǡ ǡǡ ǡǡǡȀ ǡ ȏͳͷ͵ȐǤ ǡ ǡ Ǧ ȋ Ȍ ȏͳͷͺȐǤ
(107) ȏͳͷͺȐǤ ǡ Ȁ ȋ Ͷ Ȍ ȏͳͷͻȐǤ
(108) ǡ Ǧ Ǧǡ Ǧ Ǧ Ǧ Ǧ ȏͳͲȐǤ ǡ Ȁ ȋ
(109) ȌǡȀ ʹȋ
(110) Ȍ ǦǦ ȏͳͳȂͳ͵ȐǤ ǡ Ǧ ͶǦ Ǧ Ǥ ǡ Ǧ ǡ ǦǤ ʹͲ.
(111) General introduction and outline of the thesis. 1. . mFAO deficiency ȏͳͷ͵ǡͳͶȐǤ
GERELATEERDE DOCUMENTEN
Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the authors and/or
Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine: from computational model to mice to man..
Met het eindigen van de Kaderwet in 2003 en door het goede van de Kaderwet onder te brengen in een vernieuwde en aangescherpte WGR wordt het mogelijk de
Het is wenselijk dat ouderen die kiezen voor minder uren werken of in een andere functie een stapje terugdoen met bijbehorend lager salaris, hiervoor niet gestraft
Zo hebben de Surinaamse jongeren uit de onderzoekgroep vaker problemen met hun moeder, de Turkse en Marokkaanse jongeren vaker met hun vader, In belangrijke mate wordt dit
[r]
In tabel 1 staan gegevens van drie wasdrogers: een energiezuinige wasdroger met een A-label en twee veel verkochte “gewone” wasdrogers met een C-label.. De jaarkosten van een
Met behulp van deze tabel kan men de vraag beantwoorden of het in de groep vrouwelijke werknemers boven de 40 relatief vaker voorkomt dat iemand zich wel eens oneerlijk